Network biology-inspired approaches could be used effectively in probing regulatory processes by which small molecules intervene with disease mechanisms. The present study aims at identification of key targets of type 2 diabetes mellitus (T2DM) by network analysis of the underlying protein interactome, and probing for mechanisms by which phloridzin could be critical at altering the disease phenotype. Towards this goal, we constructed a protein–protein interaction network associated with T2DM, starting from candidate genes and systems-level interactions data available. The relevance of the network constructed was verified with the help of gene ontology, node deletion, and biological essentiality studies. Using a network analysis method, MAPK1, EP300, and SMAD2 were identified as the most central proteins of potential therapeutic value. Phloridzin, a known antidiabetic agent, potentially interacts with proteins central to T2DM mechanisms. The structural understanding of interaction of phloridzin with these proteins of relevance to T2DM could provide better insight into its regulatory mechanisms and help in developing better therapeutic agents. The molecular docking results suggest that phloridzin is potentially involved in making critical interactions with MAPK1. These results could further be validated by experimental studies and could be used to design therapeutic agents for T2DM intervention.
Get full access to this article
View all access options for this article.
References
1.
Abdul-GhaniMA, DeFronzoRA. 2008. Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocrine Practice, 14:782–790.
2.
AgrawalS, DimitrovaN, NathanPet al.2008. T2D-Db: An integrated platform to study the molecular basis of Type 2 diabetes. BMC Genom, 9:320.
3.
AlbertR, JeongH, BarabasiA. 2000. Error and attack tolerance of complex networks. Nature, 406:378–382.
4.
American Diabetes Association. 2012. Standards of medical care in diabetes-2012. Diabetes Care, 35:S11–63.
5.
Arauz-PachecoC, ParrottM, RaskinP. 2004. Hypertension management in adults with diabetes-American Diabetes Association. Diabetes Care, 27:s65–67.
BergerSI, Ma'ayanA, IyengarR. 2010. Systems pharmacology of arrhythmias. Sci Signal, 3:ra30.
11.
BernsteinFC, KoetzleTF, WilliamsGJet al.1977. The Protein Data Bank: A computer-based archival file for macromolecular structures. J Mol Biol, 112:535–542.
12.
BlakeJA, BultCJ, KadinJA, RichardsonJE, EppigJT. 2011. The Mouse Genome Database (MGD): Premier model organism resource for mammalian genomics and genetics. Nucleic Acids Res, 39,Database issue:D842–848.
13.
BoyerJ, LiuRH. 2004. Apple phytochemicals and their health benefits. Nutr J, 3:1–15.
14.
BrandesU. 2001. A faster algorithm for betweenness centrality. J Math Sociol, 25:163–177.
15.
BrouwersL, IskarM, ZellerG, van NoortV, BorkP. 2011. Network neighbors of drug targets contribute to drug side-effect similarity. PloS ONE, 6:e22187.
16.
ChaoE. 2011. A paradigm shift in diabetes therapy—Dapagliflozin and other SGLT2 inhibitors. Disc Med, 11:255–263.
ChenG, DongZY, HillDJ, ZhangGH. 2009. An improved model for structural vulnerability analysis of power networks. Physica A: Statist Mech App, 388:4259–4266.
19.
ChesneyR, SacktorB, KleinzellerA. 1974. The binding of phloridzin to the isolated luminal membrane of the renal proximal tubule. Biochim Biophys Acta Biomemb, 332:263–277.
20.
ChuL-H, ChenB-S. 2008. Construction of a cancer-perturbed protein–protein interaction network for discovery of apoptosis drug targets. BMC Syst Biol, 2:56.
21.
ChungJ, UchidaE, GrammerTC, BlenisJ. 1997. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol, 17:6508–6516.
DimitrakoudisD, VranicM, KlipA. 1992. Effects of hyperglycemia on glucose transporters of the muscle: Use of the renal glucose reabsorption inhibitor phlorizin to control glycemia. J Am Soc Nephrol, 3:1078–1091.
27.
DimmerEC, HuntleyRP, BarrellDGet al.2008. The gene ontology—Providing a functional role in proteomic studies. Proteomics, 8:23–24.
28.
EdenE, NavonR, SteinfeldI, LipsonD, YakhiniZ. 2009. GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformat, 10:48.
29.
EhrenkranzJRL, LewisNG, KahnCR, RothJ. 2005. Phlorizin: A review. Diabetes/Metab Res Rev, 21:31–38.
30.
EscarpaA, GonzálezMC. 1998. High-performance liquid chromatography with diode-array detection for the determination of phenolic compounds in peel and pulp from different apple varieties. J Chromatog A, 823:331–337.
31.
EvadnieR, DamcottC, FuMet al.2007. Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: Evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes, 56:3053–3062.
32.
FlórezAF, ParkD, BhakJet al.2010. Protein network prediction and topological analysis in Leishmania major as a tool for drug target selection. BMC Bioinform, 11:484.
33.
FreemanLC. 1977. A set of measures of centrality based on betweennss. Sociometry, 40:35–41.
34.
GersteinH, JohannesM, YiQ, ZinmanBet al.2001. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA, 286:421–426.
35.
GohKI, CusickME, ValleD, ChildsB, VidalM, BarabásiAL. 2007. The human disease network. Proc Natl Acad Sci, 104:8685–8690.
36.
GoñiJ, EstebanFJ, de MendizábalNVet al.2008. A computational analysis of protein–protein interaction networks in neurodegenerative diseases. BMC Syst Biol, 2:52.
37.
GrossJL, de AzevedoMJ, SilveiroSP, CananiLH, CaramoriML, ZelmanovitzT. 2005. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care, 28:164–176.
38.
HahnMW, KernAD. 2005. Comparative genomics of centrality and essentiality in three eukaryotic protein-interaction networks. Mol Biol Evol, 22:803–806.
39.
HanJ-DJ, DupuyD, BertinN, CusickME, VidalM. 2005. Effect of sampling on topology predictions of protein–protein interaction networks. Nature Biotech, 23:839–844.
40.
HartwellLH, HopfieldJJ, LeiblerS, MurrayAW. 1999. From molecular to modular cell biology. Nature, 402:C47–52.
41.
HayesMG, PluzhnikovA, MiyakeKet al.2007. Identification of Type 2 Diabetes genes in Mexican Americans through genome-wide association studies. Diabetes, 56:3033–3044.
42.
HetényiC, van der SpoelD. 2002. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci, 11:1729–1737.
43.
HetényiC, van der SpoelD. 2006. Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett, 580:1447–1450.
44.
HolmeP, KimB, YoonC, HanS. 2002. Attack vulnerability of complex networks. Phys Rev E, 65.
45.
HongSW, IsonoM, ChenS, Iglesias-de la CruzMC, HanDC, ZiyadehFN. 2001. Increased glomerular and tubular expression of transforming growth factor-β1, its Type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol, 158:1653–1663.
46.
HonguM, FunamiN, TakahashiYet al.1998. Na(+)-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety. Chem Pharmaceut Bull, 46:1545–1555.
47.
HonguM, TanakaT, FunamiN, SaitoK, ArakawaK, MatsumotoM, TsujiharaK. 1998. Na(+)-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4′-dehydroxyphlorizin derivatives. Chem Pharmaceut Bull, 46:22–33.
48.
HormozdiariF, BerenbrinkP, PrzuljN, SahinalpSC. 2007. Not all scale-free networks are born equal: The role of the seed graph in PPI network evolution. PLoS Comput Biol, 3:e118.
49.
HuangB, SchroederM. 2006. LIGSITEcsc: Predicting ligand binding sites using the Connolly surface and degree of conservation. BMC Struct Biol, 6:1–11.
50.
HwangS, SonSW, KimSC, KimYJ, JeongH, LeeD. 2008. A protein interaction network associated with asthma. J Theoret Biol, 252:722–731.
51.
InoueH, OgawaW, OzakiMet al.2004. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nature Med, 10:168–174.
52.
JeongH, MasonSP, BarabásiAL, OltvaiZN. 2001. Lethality and centrality in protein networks. Nature, 411:41–42.
53.
JolivaltCG, LeeCA, BeiswengerKKet al.2008. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin. J Neurosci Res, 86:3265–3274.
54.
JoyMP, BrockA, IngberDE, HuangS. 2005. High-betweenness proteins in the yeast protein interaction network. J Biomed Biotech, 2005:96–103.
55.
KanehisaM, GotoS, HattoriMet al.2006. From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res, 34,Database issue:D354–357.
56.
KaurH, ChenS, XinX, ChiuJ, KhanZA, ChakrabartiS. 2006. Diabetes-induced extracellular matrix protein expression is mediated by transcription coactivator p300. Diabetes, 55:3104–3111.
57.
Keshava PrasadTS, GoelR, KandasamyKet al.2009. Human Protein Reference Database–2009 update. Nucleic Acids Res, 37,Database issue:D767–772.
58.
KimKK, KimHB. 2009. Protein interaction network related to Helicobacter pylori infection response. World J Gastroenterol, 15:4518–4528.
59.
KinoshitaT, DoiK, SugiyamaH, KinoshitaS, WadaM, NarutoS. 2011. Knowledge-based identification of the ERK2/STAT3 signal pathway as a therapeutic target for type 2 diabetes and drug discovery. Chem Biol Drug Design, 78:471–476.
60.
LilliojaS, MottD, SpraulMet al.1993. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: Prospective studies of Pima Indians. New Engl J Med, 329:1988–1992.
61.
LimD, KimN, ParkHet al.2011a. Identification of candidate genes related to bovine marbling using protein-protein interaction networks. Intl J Biol Sci, 7:992–1002.
62.
LimHS, LipGYH. 2003. Diabetes, the renin-angiotensin system and heart disease. Curr Vasc Pharmacol, 1:225–238.
63.
LiuM, LiberzonA, KongSW, LaiWR, ParkPJ, KohaneIS. 2007. Network-based analysis of affected biological processes in type 2 diabetes models. PLoS Genet, 3:e96.
64.
LiuX, WangL, ZhaoK, ThompsonPR, HwangY, MarmorsteinR. 2008. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature, 451:846–850.
65.
MallipeddiPL, JoshiM, BriggsJM. 2012. Pharmacophore based virtual screening to aid in the identification of unknown protein function. Chem Biol Drug Design, 80:828–842.
66.
MathivananS, PeriaswamyB, GandhiTKBet al.2006. An evaluation of human protein–protein interaction data in the public domain. BMC Bioinformat, 18:S19.
67.
McKusick-Nathans Institute of Genetic Medicine, JHU. 2011. http://omim.org/.
68.
MinamiH, KimJR, TadaKet al.1993. Inhibition of glucose absorption by phlorizin affects intestinal functions in rats. Gastroenterology, 105:692–697.
69.
MolitchM, DeFronzoR, FranzM, KeaneW, MogensenC, ParvingH-H. 2004. Nephropathy in diabetes. Diabetes Care, 27:s79–s83.
70.
MorrisGM, HueyR, LindstromW, SannerMF, BelewRK, GoodsellDS. 2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Computat Chem, 30:2785–2791.
71.
MorrisGM, HueyR, OlsonAJ. 2008. Using AutoDock for ligand-receptor docking. Curr Prot Bioinformat, Chapter 8,Unit 8.14.
72.
NewmanMEJ. 2005. A measure of betweenness centrality based on random walks. Social Networks, 27:39–54.
73.
NunoiK, YasudaK, AdachiTet al.2002. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol, 29:386–390.
74.
OdoniG, RitzE. 1999. Diabetic nephropathy—What have we learned in the last three decades?J Nephrol, 2:S120–124.
75.
OhoriM, KinoshitaT, OkuboMet al.2005. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun, 336:357–363.
76.
O'BoyleNM, BanckM, JamesC, MorleyC, VandermeerschT, HutchisonGR. 2011. Open Babel: An open chemical toolbox. J Cheminformat, 3:33.
77.
PlatzerA, PercoP, LukasA, MayerB. 2007. Characterization of protein-interaction networks in tumors. BMC Bioinformat, 8:224.
78.
RandhawaV, BaglerG. 2012. Identification of SRC as a potent drug target for asthma using an integrative approach of protein interactome analysis and in silico drug discovery. OMICS J Integ Biol, 16:513–526.
79.
RascheA, Al-HasaniH, HerwigR. 2008. Meta-analysis approach identifies candidate genes and associated molecular networks for type-2 diabetes mellitus. BMC Genom, 9:1–17.
80.
RastogiK, CooperR, ShiZ, VranicM. 1998. Quantitative measurement of islet glucagon response to hypoglycemia by confocal fluorescence imaging in diabetic rats: Effects of phlorizin treatment. Endocrine, 7:367–375.
81.
ReboldiG, GentileG, AngeliF, AmbrosioG, ManciaG, VerdecchiaP. 2011. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: A meta-analysis in 73,913 patients. J Hyperten, 29:1253–1269.
82.
RékaA, Albert-LászloB. 2002. Statistical mechanics of complex networks. Rev Modern Phys, 74:47–97.
83.
RichSS, NorrisJM, RotterJI. 2008. Genes associated with risk of type 2 diabetes identified by a candidate-wide association scan: as a trickle becomes a flood. Diabetes, 57:2915–2917.
84.
RossettiL, SmithD, ShulmanG, PapachristouD, DeFronzoR. 1987. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest, 79:1510–1515.
85.
SabidussiG. 1966. The centrality index of a graph. Psychometrika, 31:581–603.
86.
SantiagoA, BenitoRM. 2009. Robustness of heterogeneous complex networks. Phys A Statist Mech App, 388:2234–2242.
ShannonP, MarkielA, OzierOet al.2003. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 13:2498–2504.
89.
ShaoX, BaiN, HeK, HoC-T, YangC, SangS. 2008. Apple polyphenols, phloretin and phloridzin: New trapping agents of reactive dicarbonyl species. Chem Res Toxicol, 21:2042–2050.
90.
SharmaA, ChavaliS, TabassumR, TandonN, BharadwajD. 2010. Gene prioritization in Type 2 diabetes using domain interactions and network analysis. BMC Genom, 11:84.
ShojiT, KoboriM, ShinmotoH, TanabeM, TsushidaT. 1997. Progressive effects of phloridzin on melanogenesis in B16 mouse melanoma cells. Biosci Biotech Biochem, 61:1963–1967.
93.
SmithCL, GoldsmithC-AW, EppigJT. 2005. The Mammalian Phenotype Ontology as a tool for annotating, analyzing and comparing phenotypic information. Genome Biol, 6:R7.
94.
SouchelnytskyiS, TamakiK, EngströmU, WernstedtC, ten DijkeP, HeldinCH. 1997. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem, 272:28107–28115.
95.
TrottO, OlsonA. 2010. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem, 31:455–461.
96.
VashishtS, BaglerG. 2012. An approach for the identification of targets specific to bone metastasis using cancer genes interactome and gene ontology analysis. PLoS ONE, 7:e49401.
97.
VollenweiderP, MénardB, NicodP. 2002. Insulin resistance, defective insulin receptor substrate 2-associated phosphatidylinositol-3′ kinase activation, and impaired atypical protein kinase C (ζ/λ) activation in myotubes from obese patients with impaired glucose tolerance. Diabetes, 51:1052–1059.
98.
WallaceAC, LaskowskiRA, ThorntonJM. 1995. LIGPLOT: A program to generate schematic diagrams of protein–ligand interactions. Protein Engineer, 8:127–134.
99.
WildingJ, NorwoodP, T'joenC, BastienA, FiedorekF. 2009. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care, 32:1656–1662.
100.
WinerN, SowersJ. 2004. Epidemiology of diabetes. J Clin Pharmacol, 44:397–405.
101.
World Health Organisation-Diabetes mellitus. 2012. Fact sheet N°138. World Health Organization.
102.
WuC, ZhuJ, ZhangX. 2012. Integrating gene expression and protein–protein interaction network to prioritize cancer-associated genes. BMC Bioinform, 13:182.
103.
WuG, ChenYG, OzdamarBet al.2000. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science, 287:92–97.
104.
YuH, GreenbaumD, Xin LuH, ZhuX, GersteinM. 2004. Genomic analysis of essentiality within protein networks. Trends Genet, 20:227–231.
105.
YuH, KimPM, SprecherE, TrifonovV, GersteinM. 2007. The importance of bottlenecks in protein networks: Correlation with gene essentiality and expression dynamics. PLoS Comput Biol, 3:e59.
106.
YueY, LiuJ, FanJ, YaoX. 2011. Binding studies of phloridzin with human serum albumin and its effect on the conformation of protein. J Pharmaceut Biomed Anal, 56:336–342.
107.
ZhaoL, ParkK, LaiY-C. 2004. Attack vulnerability of scale-free networks due to cascading breakdown. Phys Rev E, 70:2–5.
108.
ZhouF, LiG-Y, GaoZ-Zet al.2012. The TGFβ1/Smad/CTGF pathway and corpus cavernosum fibrous-muscular alterations in rats with streptozotocin-induced diabetes. J Androl, 33:651–659.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
